霍奇金病患者血清白细胞介素-2受体（CD25）水平，特别涉及年龄与预后
Serum levels of interleukin-2 receptor (CD 25) in patients with Hodgkin's disease, with special reference to age and prognosis.
作者信息
Enblad G, Sundström C, Gronowitz S, Glimelius B
机构信息
Department of Oncology, University of Uppsala, Akademiska sjukhuset, Sweden.
出版信息
Ann Oncol. 1995 Jan;6(1):65-70. doi: 10.1093/oxfordjournals.annonc.a059044.
BACKGROUND
The serum levels of soluble interleukin-2 receptor (S-sIL-2R) have been shown to be related to clinical outcome in Hodgkin's disease (HD). sIL-2R may be involved in or aggravate the immunodeficiency seen in HD patients. This immunodeficiency is most pronounced in elderly patients.
PATIENTS AND METHODS
S-sIL-2R was determined in 127 untreated patients with HD, diagnosed between 1979 and 1991, in order to evaluate its prognostic value in relation to other known prognostic variables with special emphasis on the elderly.
RESULTS
S-sIL-2R levels were significantly higher in patients with stages III-IV and with B-symptoms (p < 0.001) but not in patients over 60 years of age. In multivariate analyses, S-sIL-2R, stage and S-orosomucoid were the most important prognostic factors in all patients and S-sIL-2R was the only prognostic factor in patients over the age of 60.
CONCLUSIONS
The results indicate a future role for estimation of S-sIL-2R in the management of patients with HD.
背景
可溶性白细胞介素-2受体（S-sIL-2R）的血清水平已被证明与霍奇金淋巴瘤（HD）的临床结局相关。sIL-2R可能参与或加重HD患者中出现的免疫缺陷。这种免疫缺陷在老年患者中最为明显。
患者与方法
对1979年至1991年间诊断的127例未经治疗的HD患者测定S-sIL-2R，以评估其与其他已知预后变量相关的预后价值，特别关注老年患者。
结果
III-IV期和有B症状的患者S-sIL-2R水平显著更高（p<0.001），但60岁以上患者中并非如此。在多变量分析中，S-sIL-2R、分期和S-orosomucoid是所有患者中最重要的预后因素，而S-sIL-2R是60岁以上患者唯一的预后因素。
结论
结果表明S-sIL-2R评估在HD患者管理中具有未来作用。
Zotero 插件